Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest

Human Molecular Genetics

Volumn 22, Issue 12, 2013, Pages 2451-2461

  Nizialek, Emily ^a,c   Peterson, Charissa ^a   Mester, Jessica ^a,b   Downes Kelly, Erinn ^a   Eng, Charis ^a,b,c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CELL CYCLE G2 PHASE; CONTROLLED STUDY; COWDEN SYNDROME; FAMILY HISTORY; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERM LINE; HEMIZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KLLN GENE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84878519844     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt097     Document Type: Article

References (53)

1. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA Cancer J. Clin., 61, 69-90.
2. Narod, S.A. (2006) Modifiers of risk of hereditary breast cancer. Oncogene, 25, 5832-5836.
3. Stratton, M.R. and Rahman, N. (2008) The emerging landscape of breast cancer susceptibility. Nat. Genet., 40, 17-22.
4. Hemminki K., Granstrom C.(2003) Familial breast cancer: scope for more susceptibility genes? Breast Cancer Res. Treat. 82 17-22.
5. Zbuk, K.M. and Eng, C. (2007) Cancer phenomics: RET and PTEN as illustrative models. Nat. Rev. Cancer, 7, 35-45.
6. Antoniou, A.C. and Easton, D.F. (2006) Models of genetic susceptibility to breast cancer. Oncogene, 25, 5898-5905.
7. Zhang, B., Beeghly-Fadiel, A., Long, J. and Zheng, W. (2011) Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol., 12, 477-488.
8. Tan, M.H., Mester, J.L., Ngeow, J., Rybicki, L.A., Orloff, M.S. and Eng, C. (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res., 18, 400-407.
9. Tan, M.H., Mester, J., Peterson, C., Yang, Y., Chen, J.L., Rybicki, L.A., Milas, K., Pederson, H., Remzi, B., Orloff, M.S. et al. (2011) A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am. J. Hum. Genet., 88, 42-56.
10. Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M. et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16, 64-67.
11. Cho, Y.J. and Liang, P. (2008) Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc. Natl. Acad. Sci. USA, 105, 5396-5401.
12. Bennett, K.L., Mester, J. and Eng, C. (2010) Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA, 304, 2724-2731.
13. Bennett, K.L., Campbell, R., Ganapathi, S., Zhou, M., Rini, B., Ganapathi, R., Neumann, H.P. and Eng, C. (2011) Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer, 50, 654-661.
14. Gingold, H. and Pilpel, Y. (2011) Determinants of translation efficiency and accuracy. Mol. Syst. Biol., 7, 481.
15. Nakamura, Y., Gojobori, T. and Ikemura, T. (2000) Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res., 28, 292.
16. Foulkes, W.D., Stefansson, I.M., Chappuis, P.O., Begin, L.R., Goffin, J.R., Wong, N., Trudel, M. and Akslen, L.A. (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst., 95, 1482-1485.
17. Cleator, S., Heller, W. and Coombes, R.C. (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol., 8, 235-244.
18. Conrad, D.F., Pinto, D., Redon, R., Feuk, L., Gokcumen, O., Zhang, Y., Aerts, J., Andrews, T.D., Barnes, C., Campbell, P. et al. (2010) Origins and functional impact of copy number variation in the human genome. Nature, 464, 704-712.
19. McCarroll, S.A., Kuruvilla, F.G., Korn, J.M., Cawley, S., Nemesh, J., Wysoker, A., Shapero, M.H., de Bakker, P.I., Maller, J.B., Kirby, A. et al. (2008) Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat. Genet., 40, 1166-1174.
20. Kuiper, R.P., Ligtenberg, M.J., Hoogerbrugge, N. and Geurts van Kessel, A. (2010) Germline copy number variation and cancer risk. Curr. Opin. Genet. Dev., 20, 282-289.
21. Venkatachalam, R., Ligtenberg, M.J., Hoogerbrugge, N., Schackert, H.K., Gorgens, H., Hahn, M.M., Kamping, E.J., Vreede, L., Hoenselaar, E., van der Looij, E. et al. (2010) Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early-onset familial colorectal cancer. Gastroenterology, 139, 2221-2224.
22. Thompson, E.R., Gorringe, K.L., Choong, D.Y., Eccles, D.M., Mitchell, G. and Campbell, I.G. (2012) Analysis of KLLN as a high-penetrance breast cancer predisposition gene. Breast Cancer Res. Treat., 134, 543-547.
23. Venkatachalam, S., Shi, Y.P., Jones, S.N., Vogel, H., Bradley, A., Pinkel, D. and Donehower, L.A. (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J., 17, 4657-4667.
24. Duan, J., Wainwright, M.S., Comeron, J.M., Saitou, N., Sanders, A.R., Gelernter, J. and Gejman, P.V. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Mol. Genet., 12, 205-216.
25. Chamary, J.V. and Hurst, L.D. (2005) Evidence for selection on synonymous mutations affecting stability of mRNA secondary structure in mammals. Genome Biol., 6, R75.
26. Yarden, R.I., Pardo-Reoyo, S., Sgagias, M., Cowan, K.H. and Brody, L.C. (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat. Genet., 30, 285-289.
27. Liu, Q., Guntuku, S., Cui, X.S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A. et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev., 14, 1448-1459.
28. Bartek, J. and Lukas, J. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-429.
29. Nathanson, K.L. and Weber, B.L. (2001) 'Other' breast cancer susceptibility genes: searching for more holy grail. Hum. Mol. Genet., 10, 715-720.
30. Heinemeyer, T., Wingender, E., Reuter, I., Hermjakob, H., Kel, A.E., Kel, O.V., Ignatieva, E.V., Ananko, E.A., Podkolodnaya, O.A., Kolpakov, F.A. et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res., 26, 362-367.
31. Schug, J. (2002) Using TESS to predict transcription factor binding sites in DNA sequence. In Baxevanic, A. (ed), Current Protocols in Bioinformatics. J. Wiley and Sons, Hoboken, New Jersey, pp. 2.6.1- 2.6.15.
32. Sharrocks, A.D. (2001) The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol., 2, 827-837.
33. Tsutsui, S., Inoue, H., Yasuda, K., Suzuki, K., Higashi, H., Era, S. and Mori, M. (2005) Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology, 68, 398-404.
34. Perren, A., Weng, L.P., Boag, A.H., Ziebold, U., Thakore, K., Dahia, P.L., Komminoth, P., Lees, J.A., Mulligan, L.M., Mutter, G.L. et al. (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol., 155, 1253-1260.
35. Salmena, L., Carracedo, A. and Pandolfi, P.P. (2008) Tenets of PTEN tumor suppression. Cell, 133, 403-414.
36. Dent, P., Tang, Y., Yacoub, A., Dai, Y., Fisher, P.B. and Grant, S. (2011) CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol. Interv., 11, 133-140.
37. Ma, C.X., Cai, S., Li, S., Ryan, C.E., Guo, Z., Schaiff, W.T., Lin, L., Hoog, J., Goiffon, R.J., Prat, A. et al. (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J. Clin. Invest., 122, 1541-1552.
38. TCGA Network (2012) Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70.
39. Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K.K., Carter, S.L., Frederick, A.M., Lawrence, M.S., Sivachenko, A.Y., Sougnez, C., Zou, L. et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature, 486, 405-409.
40. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J. et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science, 318, 1108-1113.
41. Weigman, V.J., Chao, H.H., Shabalin, A.A., He, X., Parker, J.S., Nordgard, S.H., Grushko, T., Huo, D., Nwachukwu, C., Nobel, A. et al. (2012) Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res. Treat., 133, 865-880.
42. Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y. et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 486, 346-352.
43. Han, W., Han, M.R., Kang, J.J., Bae, J.Y., Lee, J.H., Bae, Y.J., Lee, J.E., Shin, H.J., Hwang, K.T., Hwang, S.E. et al.. (2006) Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer, 6, 92.
44. Feilotter, H.E., Coulon, V., McVeigh, J.L., Boag, A.H., Dorion-Bonnet, F., Duboue, B., Latham, W.C., Eng, C., Mulligan, L.M. and Longy, M. (1999) Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br. J. Cancer, 79, 718-723.
45. Garcia, J.M., Silva, J.M., Dominguez, G., Gonzalez, R., Navarro, A., Carretero, L., Provencio, M., Espana, P. and Bonilla, F. (1999) Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res. Treat., 57, 237-243.
46. Ni, Y., Zbuk, K.M., Sadler, T., Patocs, A., Lobo, G., Edelman, E., Platzer, P., Orloff, M.S., Waite, K.A. and Eng, C. (2008) Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am. J. Hum. Genet., 83, 261-268.
47. Tang, Y. and Eng, C. (2006) p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res., 66, 6139-6148.
48. He, X., Ni, Y., Wang, Y., Romigh, T. and Eng, C. (2011) Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Hum. Mol. Genet., 20, 80-89.
49. Shukla, S.J. and Dolan, M.E. (2005) Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics, 6, 303-310.
50. Goldstone, S., Pavey, S., Forrest, A., Sinnamon, J. and Gabrielli, B. (2001) Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene, 20, 921-932.
51. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E. et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov., 2, 401-404.
52. Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J.C., Huang, J.H., Alexander, S. et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA, 104, 20007-20012.
53. Li, B. and Dewey, C.N. (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics, 12, 323.